About This Page
This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.
The Bottom Line
- An elevated INR or PTT must be interpreted with bleeding status, medication exposure, liver function, vitamin K status, DIC screen and mixing studies — identify dangerous coagulopathy without reflexively correcting harmless lab abnormalities.
- Start with acuity and stability before narrowing the differential.
- Use CBC with differential, smear, coagulation studies and targeted tests according to the presentation pattern.
- Escalate urgently for abnormal smear, systemic red flags, major bleeding, sepsis, thrombosis, neurologic symptoms or suspected malignancy.
- Management is cause-directed and should follow Canadian transfusion, thrombosis and cancer diagnostic pathway principles.
Approach to the Presentation
Abnormal Coagulation Studies (Elevated INR / PTT) is approached as a clinical presentation rather than as a single diagnosis. Begin by assessing stability, bleeding or thrombosis risk, infection/sepsis features, medication exposures, pregnancy status where relevant, and systemic red flags. Then use the pattern of the abnormality — CBC lineage, smear morphology, coagulation pathway, node distribution, spleen size, or VTE pre-test probability — to select focused investigations. For MCCQE1, the safest answer is usually the one that identifies must-not-miss disease while avoiding reflex treatment of an isolated laboratory value.
Differential Diagnosis
| diagnosis | likelihood | key features | distinguishing test |
|---|---|---|---|
| DIC | must-not-miss | Sepsis, trauma, obstetric emergency, malignancy; bleeding from lines, purpura, thrombosis, organ dysfunction. | Prolonged PT/aPTT, low platelets, low fibrinogen, high D-dimer, schistocytes. |
| Warfarin excess or vitamin K antagonist effect | must-not-miss | High INR, bleeding or high risk, medication/diet changes, antibiotics, liver disease, overdose. | INR pattern; medication history; response to vitamin K/PCC when indicated. |
| Heparin effect or overdose | must-not-miss | UFH exposure, prolonged aPTT, bleeding, renal/ICU context; LMWH may not prolong aPTT reliably. | aPTT or anti-Xa depending on agent and local practice. |
| Acquired factor inhibitor | must-not-miss | Older adult/postpartum/autoimmune/malignancy with new severe soft tissue bleeding and isolated prolonged aPTT. | Mixing study does not correct; low factor VIII; inhibitor assay. |
| Liver disease / synthetic failure | common | Elevated INR with thrombocytopenia, low albumin, jaundice, ascites, alcohol/hepatitis risk; bleeding and thrombosis coexist. | Liver tests, bilirubin, albumin, platelet count, ultrasound; factor V may help. |
| Vitamin K deficiency | common | Malnutrition, cholestasis, prolonged antibiotics, newborn, fat malabsorption; PT rises first. | INR improves with vitamin K; clinical context. |
| DOAC effect | common | Apixaban/rivaroxaban/dabigatran use; routine PT/aPTT variably affected; renal dysfunction increases exposure. | Medication timing, renal function, drug-specific anti-Xa or dilute thrombin time where available. |
| Lupus anticoagulant / antiphospholipid syndrome | less common | Prolonged aPTT but thrombosis/recurrent pregnancy morbidity rather than bleeding. | Mixing study often fails to correct; lupus anticoagulant and antiphospholipid antibody testing. |
| Inherited haemophilia A/B or factor XI deficiency | less common | Lifelong bleeding, hemarthroses, delayed post-procedure bleeding, family history; isolated prolonged aPTT. | Mixing study corrects; factor VIII/IX/XI levels. |
| Pre-analytical error / sample contamination | less common | Unexpected result, line draw contaminated with heparin, underfilled citrate tube, no bleeding history. | Repeat sample from peripheral venipuncture. |
Red Flags & Key History
Symptoms
Intracranial symptoms, GI bleeding, hematuria, airway bleeding or expanding haematoma
Sepsis, trauma, obstetric catastrophe or malignancy with bleeding — DIC concern
New severe soft tissue bleeding with isolated prolonged aPTT — acquired haemophilia
Warfarin, DOAC, heparin, antiplatelet, antibiotic, anticonvulsant or herbal exposure
Jaundice, ascites, alcohol use, hepatitis risk, malnutrition or cholestasis
Thrombosis or recurrent pregnancy morbidity with prolonged aPTT — lupus anticoagulant pattern
Signs
Hemodynamic instability or signs of major bleeding
Purpura fulminans, bleeding from IV sites or acral ischemia
Large muscle haematomas or compartment syndrome signs
Stigmata of chronic liver disease
Hemarthrosis in male patient with lifelong history
Approach to Investigation
First-line
Repeat PT/INR and aPTT if unexpectedExclude sample error, heparin contamination, underfilled tube and lab artefact.
CBC with platelet count and smearDetect thrombocytopenia, anaemia from bleeding, schistocytes, blasts or clumping.
Fibrinogen and D-dimerEssential for DIC assessment and consumptive coagulopathy.
Creatinine/eGFR, liver tests, bilirubin, albuminAssess DOAC accumulation, liver synthetic failure, cholestasis and systemic illness.
Second-line
Mixing studyCorrection suggests factor deficiency; non-correction suggests inhibitor/lupus anticoagulant.
Factor assays and inhibitor testingFactor VIII/IX/XI, factor VII, factor V; Bethesda inhibitor assay when acquired inhibitor suspected.
Drug-specific anticoagulant assaysAnti-Xa for heparin/selected DOACs; thrombin time/dilute thrombin time for dabigatran where available.
Specialist
Haematology/transfusion medicine consultationMajor bleeding, DIC, factor inhibitor, urgent procedure with complex coagulopathy or reversal uncertainty.
Hepatology consultationSevere liver synthetic failure, acute liver failure, variceal bleeding or transplant-level concern.
Management Principles
Choosing Wisely Canada transfusion medicine + Canadian Blood Services clinical guide1
Non-bleeding abnormal tests
- Do not reflexively correct mild INR/aPTT abnormalities with plasma when the patient is not bleeding and no urgent high-risk procedure is planned.
- Repeat unexpected results and address reversible causes.
- Assess procedural bleeding risk and local thresholds rather than using a universal cutoff.
2
Major bleeding or urgent procedure
- Warfarin major bleeding: PCC plus IV vitamin K according to local protocol.
- Heparin major bleeding: stop heparin; protamine for UFH and selected LMWH situations.
- DOAC major bleeding: hold drug, supportive measures, consider specific reversal/PCC with specialist input.
- DIC: treat underlying cause and support with platelets, plasma or cryoprecipitate/fibrinogen if needed.
3
Specific disorders
- Vitamin K deficiency: replace vitamin K and address malabsorption/cholestasis/antibiotics.
- Acquired factor inhibitor: urgent haematology; bypassing agents and immunosuppression may be needed.
- Lupus anticoagulant without bleeding: do not correct aPTT; evaluate thrombosis risk.
Complications & Pitfalls
- Abnormal coagulation tests do not equal bleeding risk: lupus anticoagulant is associated with thrombosis.
- Do not give plasma for mildly elevated INR in a non-bleeding patient.
- Mixing studies matter: they separate deficiency from inhibitors.
- Liver disease is not auto-anticoagulation: patients can bleed and clot.
- Check anticoagulant timing and renal function.
MCCQE1 Exam Tips
- 1Isolated prolonged PT/INR = warfarin/vitamin K/factor VII/liver; isolated prolonged aPTT = heparin/haemophilia/inhibitor/lupus anticoagulant.
- 2Prolonged PT and aPTT plus low fibrinogen and high D-dimer = DIC.
- 3Mixing study corrects = factor deficiency; does not correct = inhibitor or lupus anticoagulant.
- 4Lupus anticoagulant prolongs aPTT but causes thrombosis, not bleeding.
- 5Major warfarin bleeding: PCC + vitamin K.
- 6Choosing Wisely Canada: do not transfuse plasma simply to correct a mildly elevated INR in a non-bleeding patient.
practicetest your knowledge on abnormal coagulation studies (elevated inr / ptt)Apply what you've learnt with MCCQE1-style questions from the iatroX Q-Bank — haematologic & oncologic and beyond.
open q-bank